W.E. Fibbe

1.3k total citations
28 papers, 969 citations indexed

About

W.E. Fibbe is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, W.E. Fibbe has authored 28 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Genetics and 9 papers in Oncology. Recurrent topics in W.E. Fibbe's work include Mesenchymal stem cell research (11 papers), Hematopoietic Stem Cell Transplantation (10 papers) and Multiple Myeloma Research and Treatments (5 papers). W.E. Fibbe is often cited by papers focused on Mesenchymal stem cell research (11 papers), Hematopoietic Stem Cell Transplantation (10 papers) and Multiple Myeloma Research and Treatments (5 papers). W.E. Fibbe collaborates with scholars based in Netherlands, Italy and Belgium. W.E. Fibbe's co-authors include Marinus H. J. van Oers, Jan J. Cornelissen, H M Lokhorst, Marlies E. J. Reinders, Ton J. Rabelink, A Schattenberg, LF Verdonck, I. Steele Russell, Hans C. van Houwelingen and Dave L. Roelen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

W.E. Fibbe

27 papers receiving 948 citations

Peers

Countries citing papers authored by W.E. Fibbe

Since Specialization

Citations

This map shows the geographic impact of W.E. Fibbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.E. Fibbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.E. Fibbe more than expected).

Fields of papers citing papers by W.E. Fibbe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.E. Fibbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.E. Fibbe. The network helps show where W.E. Fibbe may publish in the future.

Co-authorship network of co-authors of W.E. Fibbe

This figure shows the co-authorship network connecting the top 25 collaborators of W.E. Fibbe. A scholar is included among the top collaborators of W.E. Fibbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.E. Fibbe. W.E. Fibbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparability of MSC manufacturing protocols for clinical trials 2020 ·Cytotherapy ·Melissa van Pel, (unknown), (unknown), (unknown), (unknown), W.E. Fibbe, Jaap Jan Zwaginga	1
2	Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study 2015 ·Journal of Translational Medicine ·Marlies E. J. Reinders, (unknown), (unknown), Helene Roelofs, Sebastiaan Heidt, Dave L. Roelen, Maarten L. Zandvliet, Volkert A.L. Huurman, W.E. Fibbe, Cees van Kooten, Frans H.J. Claas, Ton J. Rabelink, Johan W. de Fijter	58
3	Multiple infusions of haploidentical mesenchymal stromal cells are not immunogenic in children undergoing myeloablative stem cell transplantation 2010 ·Bone Marrow Transplantation ·L.M. Ball, Maria Ester Bernardo, Maarten J. D. van Tol, Helene Roelofs, Jaap Jan Zwaginga, Franco Locatelli, W.E. Fibbe, R. Maarten Egeler	1
4	S40 Phase I results of intravenous autologous bone marrow derived mesenchymal stromal cell treatment in refractory Crohn's disease 2010 ·Marjolijn Duijvestein, Manon E. Wildenberg, Anne Christine W. Vos, Auke P. Verhaar, Herma H. Fidder, Jaap Jan Zwaginga, Helene Roelofs, W.E. Fibbe, Gijs R. van den Brink, Daan W. Hommes	2
5	Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors 2009 ·Haematologica ·Maria Antonietta Avanzini, Maria Ester Bernardo, Angela Cometa, Cesare Perotti, Nadia Zaffaroni, Francesca Novara, Livia Visai, Antonia Moretta, Claudia Del Fante, Raffaella Villa, L.M. Ball, W.E. Fibbe, Rita Maccario, Franco Locatelli	99
6	Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation 2009 ·Nephrology Dialysis Transplantation ·Marlies E. J. Reinders, W.E. Fibbe, Ton J. Rabelink	65
7	Impaired Effector Memory T-Cell Regulation Facilitates Graft Versus Host Disease in CCR7-Deficient Bone Marrow Transplant Chimeras 2009 ·Transplantation ·Saskia C.A. de Jager, Kirsten Canté-Barrett, Ilze Bot, Cathrine Husberg, (unknown), Peter J. van Santbrink, Arne Yndestad, (unknown), Johan Kuiper, Theo J.C. van Berkel, Martin Lipp, Jaap Jan Zwaginga, W.E. Fibbe, Pål Aukrust, Erik A.L. Biessen	4
8	Evaluation of ‘out-of-specification’ CliniMACS CD34-selection procedures of hematopoietic progenitor cell-apheresis products 2008 ·Cytotherapy ·E Braakman, Gerrit‐Jan Schuurhuis, Frank Preijers, Carlijn Voermans, Koen Theunissen, Ivan Van Riet, W.E. Fibbe, Ineke Slaper‐Cortenbach	7
9	Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells 2008 ·Human Immunology ·Dave L. Roelen, Barbara J. van der Mast, (unknown), (unknown), Michael Eikmans, Els van Beelen, (unknown), W.E. Fibbe, Humphrey H.H. Kanhai, Sicco A. Scherjon, Frans H.J. Claas	58
10	Interferon-α as maintenance therapy in patients with multiple myeloma 2005 ·Annals of Oncology ·C. G. Schaar, Hanneke C. Kluin‐Nelemans, (unknown), Saskia le Cessie, W.P.M. Breed, W.E. Fibbe, W.A. van Deijk, M. Fickers, K. J. Roozendaal, P. W. Wijermans	41
11	Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM. 2004 ·Blood ·Pieter Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Reinier Raymakers, Gregor Verhoef, Ron Schaafsma, Marinus van Oers, (unknown), W.E. Fibbe, Shulamit Wittebol, (unknown), Douwe H. Biesma, Joke W. Baars, Harry C. Schouten, Petra H.M. Westveer, Monique Steijaert, Henk M. Lokhorst	8
12	Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience. 2001 ·PubMed ·Jacob M. van Laar, (unknown), W.E. Fibbe, F C Breedveld	12
13	Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome 2000 ·Journal of Clinical Oncology ·H M Lokhorst, A Schattenberg, Jan J. Cornelissen, Marinus H. J. van Oers, W.E. Fibbe, I. Steele Russell, (unknown), LF Verdonck	217
14	SERUM TRANSFORMING GROWTH FACTOR-??1 LEVELS IN BONE MARROW TRANSPLANT RECIPIENTS CORRELATE WITH BLOOD CELL COUNTS AND CHRONIC GRAFT-VERSUS-HOST DISEASE1 1999 ·Transplantation ·(unknown), W.E. Fibbe, Hans C. van Houwelingen, (unknown)	61
15	Improved survival of lethally irradiated recipient mice transplanted with circulating progenitor cells mobilized by IL-8 after pretreatment with stem cell factor. 1996 ·PubMed ·L. Laterveer, (unknown), I. J. D. Lindley, Malcolm Hamilton, Roel Willemze, W.E. Fibbe	31
16	High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma 1995 ·Annals of Hematology ·Roel Willemze, J. M. J. M. Zijlmans, G. J. den Ottolander, Hanneke C. Kluin‐Nelemans, J.H. Frederik Falkenburg, (unknown), (unknown), W.E. Fibbe	14
17	High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma 1995 ·Annals of Hematology ·Rein Willemze, J. M. J. M. Zijlmans, G. J. den Ottolander, Hanneke C. Kluin‐Nelemans, J.H. Frederik Falkenburg, (unknown), (unknown), W.E. Fibbe	1
18	Urinary symptoms due to leukemic infiltration of the prostate A case report 1993 ·Annals of Hematology ·E. H. Eddes, W.E. Fibbe, (unknown), J. Zwartendijk	3
19	Comparison of intensive consolidation therapy and autologous bone marrow transplantation in acute myeloid leukaemia. The Leiden experience. 1989 ·PubMed ·R. Willemze, W.E. Fibbe, Dick J. Richel, Hanneke C. Kluin‐Nelemans, (unknown)	4
20	Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes. 1989 ·The Journal of Immunology ·P.J. Voogt, J.H. Frederik Falkenburg, W.E. Fibbe, W. F. J. Veenhof, Mary Jo Hamilton, B.A. Van Krimpen, R. L. H. Bolhuis	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact